Physician profile
Sandeep Saha
NPI 1679685101
$52,076.82
in general payments reported to CMS, 2019-2025
38 companies · $14K in 2025
The $14K reported for 2025 was more than what 85% of Clinical Cardiac Electrophysiology providers received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,437 · 2020: $416 · 2021: $2,472 · 2022: $4,665 · 2023: $10K · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Travel and Lodging: $10K · Food and Beverage: $6,212 · Consulting Fee: $4,500 · Education: $22.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,213.00 |
| Travel and Lodging | $10,138.35 |
| Food and Beverage | $6,212.08 |
| Consulting Fee | $4,500.00 |
| Education | $22.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $40,778.75 | 2021-2025 | Linq II, Attain Command + Surevalve, Pulseselect |
| Medtronic Vascular, INC. | $3,746.61 | 2019-2020 | |
| Boston Scientific Corporation | $2,181.81 | 2019-2025 | Watchman Access System, Watchman |
| Abbott Laboratories | $1,681.79 | 2019-2025 | Na, Confirm Rx, Jot Dx |
| Novartis Pharmaceuticals Corporation | $1,308.14 | 2019-2025 | |
| Biotronik INC. | $360.71 | 2019-2024 | Acticor 7 Vr-T Dx, Edora 8 Dr-T, Amvia Edge |
| Cordis US Corp. | $310.22 | 2021-2025 | Mynx Control Venous, Mynx Control |
| Astrazeneca Pharmaceuticals LP | $237.36 | 2019-2022 | |
| Edwards Lifesciences Corporation | $151.39 | 2024 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $133.10 | 2022-2023 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $123.82 | 2019-2021 | |
| Pfizer INC. | $108.88 | 2019-2024 | |
| Cardiva Medical, INC. | $107.91 | 2022-2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $107.64 | 2019-2023 | Repatha |
| Amarin Pharma, INC. | $76.05 | 2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Saha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.